Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyclacel Pharmaceuticals Inc.

www.cyclacel.com

Latest From Cyclacel Pharmaceuticals Inc.

What Does 2019 Hold For Biopharma?

Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.

C-Suite Speaks Business Strategies

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Innovation Market Intelligence

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Cyclacel Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cyclacel Pharmaceuticals Inc.
  • Senior Management
  • Spiro Rombotis, Pres. & CEO
    Paul McBarron, EVP, Fin. & COO
    Judy Chiao, MD, VP, Clin. Dev. & Reg. Affairs
    Susan Davis, PhD, Sr. Dir., Bus. Dev.
  • Contact Info
  • Cyclacel Pharmaceuticals Inc.
    Phone: (908) 517-7330
    200 Connell Dr.
    #1500
    Berkeley Heights, NJ 07922
    USA
UsernamePublicRestriction

Register